COVID19NCT04414657
USZ BioResource COVID-19
An observational study of COVID19, run by Regina Grossmann at 1 site in Switzerland.
Trial summary
Mono-centric. Blood sampling for biobank development, including linkage to patient data (resource for research on COVID19). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID19
- What is being tested?
- blood sampling for biobank
- How many people
- 150 participants
- Where
- 1 siteSwitzerland
- Study dates
- 9 Apr 2020to 30 Sep 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: SARS-CoV-2 infektion (according to WHO guideline)
Who may be able to join
- m/f age > 18 years
- SARS-CoV-2 infektion (according to WHO guideline)
- hospitalisation, general ward
- acceptable language knowledge
- voluntary IFC and biobank appendix
Who cannot join
- contra indication for blood sampling
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Zurich, Clinical Trials Center
Zurich, 8091
About this study
Official title: Development of a SARS-CoV-2 Research Biobank and Databank
Mono-centric. Blood sampling for biobank development, including linkage to patient data (resource for research on COVID19).
- Conditions
- COVID19
- Being tested
- blood sampling for biobank
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood sampling for biobankOther
blood sampling for biobank
What is being measured
The primary outcome is the main question the study is designed to answer.
blood sampling for biobank
development of a biobank
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2020
- Study start9 Apr 2020
- Primary completion30 Sep 2021
- Study completion30 Sep 2021
Why it stopped: sufficient patient number reached; flattening out of pandemic in Switzerland
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Regina Grossmann
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Regina Grossmann, University of Zurich
- Investigators
- Regina Grossmann, Dr med, Study director, Head of Clinical Trials Center University Hospital Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04414657
- Sponsor's protocol ID
- CTC HFV2
- Status last verified
- Nov 2022
- First submitted
- 2 Jun 2020
- Last updated
- 14 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of a SARS-CoV-2 Research Biobank and Databank
- ClinicalTrials.gov ID
- NCT04414657
- Acronym / sponsor ID
- CTC HFV2
- Conditions
- COVID19
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: sufficient patient number reached; flattening out of pandemic in Switzerland
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Regina GrossmannUniversity, hospital or other
- Study start
- 9 Apr 2020 (actual)
- Primary completion
- 30 Sep 2021 (actual)
- Study completion
- 30 Sep 2021 (actual)
- First posted
- 4 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mono-centric. Blood sampling for biobank development, including linkage to patient data (resource for research on COVID19).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- SARS-CoV-2 infektion (according to WHO guideline)
Key inclusion criteria (5 listed)
- m/f age > 18 years
- SARS-CoV-2 infektion (according to WHO guideline)
- hospitalisation, general ward
- acceptable language knowledge
- voluntary IFC and biobank appendix
Key exclusion criteria (1 listed)
- contra indication for blood sampling
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood sampling for biobankblood sampling for biobank | Other | – |
Primary outcome
blood sampling for biobank
Time frame: 2 years
development of a biobank
Results and safety
The study was stopped early (reason given: sufficient patient number reached; flattening out of pandemic in Switzerland). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2022.
- Individual participant dataSharing planned: No
Related trials for COVID19
RecruitingPhase 2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
SARS-CoV-2
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
Recruiting
RSV Burden in Outpatient and Hospital Settings
RSV Infection, Children, Only
Active, not recruitingObservational study
Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
COVID-19 Vaccination
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Regina Grossmann, Dr med study director
Head of Clinical Trials Center University Hospital Zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID19, run by Regina Grossmann at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 14 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: sufficient patient number reached; flattening out of pandemic in Switzerland). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
blood sampling for biobank (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2022.